Cure8 trial brief
Sleep timing and morning light are modifiable, nonpharmacologic factors that could influence IBD quality of life and symptoms. If effective, a simple at-home light therapy could be an accessible adjunct to usual care.
Adults with Crohn’s disease or ulcerative colitis interested in sleep interventions; clinicians and researchers studying behavioral therapies for IBD.
This is a completed, randomized-style interventional pilot conducted at the University of Michigan enrolling adults with biopsy-proven IBD who had active symptoms and impaired IBD-specific quality of life.
The intervention arm used 1 hour of morning light therapy at home daily with the Re-Timer device for 4 weeks; the comparator arm continued usual sleep schedules for 4 weeks. The registered primary outcome was change in the Short IBD Questionnaire (SIBDQ) measured at baseline and about 36 days.
The trial excluded people with certain eye conditions, recent light therapy, severe psychiatric disorders, pregnancy, recent night-shift work or travel across time zones, and several other medical or sleep-disorder risks. Planned enrollment was 64 and the study record is marked completed.
The registry entry summarizes design and eligibility but does not provide results in this record.
This record is a clinicaltrials.gov trial entry that describes the intervention, eligibility, and primary outcome (SIBDQ) but does not include outcome data in the registry entry. The study was a small pilot with planned enrollment of 64.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The trial tests a palatable elemental diet (mBIOTA) as a non-drug approach for treating outpatient IBD flares, which could reduce reliance on steroids and other medications if shown effective and tolerable.
Dietary components and processed vegetarian/vegan products may alter the gut microbiome and intestinal barrier — both are relevant to IBD. This study will directly compare common vegan products and meat substitutes with...
Depression is common in people with IBD and can worsen quality of life and disease outcomes. This trial explores whether mirtazapine—an antidepressant thought to have favorable gastrointestinal tolerability—can be...
